@DadJoke
The judgement was fairly straightforward. If a doctor, a child, and the child's parents all agree that a particular medical treatment is best for that child, you don't need a court order to proceed. Take off your GC hats and imagine if that wasn't the case for any other condition.
*@gardenbird48*
Yes, there are NICE guidelines.
www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/08/clinical-com-pol-16046p.pdf
"New" is not experimental.
"Hormone blockers, by contrast [to sex hormones], have largely been considered free of long-term harm based on generations of follow-up studies with the large population of individuals prescribed such drugs for precocious puberty"
Dadjoke
That is NHS England - not NICE. NICE have confirmed that they have no guidelines for use of GnRH to treat gender dysphoria in children.
Secondly, according to this Policy Statement at the top of the document, this is not about puberty blockers
commission cross sex hormones for young people with continuing gender dysphoria from around their 16th birthday.
They are mentioned further down but I haven't got time to wade through the whole thing especially as it is nothing to do with the NICE guidelines I mentioned. Feel free to show me the section where NHS England have published guidelines for use of GnRH in children under 16.
Policy Statement
NHS England will, as part of the Gender Identity Development Service for Children and Adolescents, commission cross sex hormones for young people with continuing gender dysphoria from around their 16th birthday subject to individuals meeting the eligibility and readiness criteria as set out in Section 6 of this document. In exercising this discretion, the specialist multi-disciplinary team will be cognisant that international guidelines recommend the prescribing of cross sex hormones to gender variant young people at ’around 16 years’. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources. This policy document outlines the arrangements for funding of this treatment for the population in England.
Re. your last statement - have you even read the information about the harms Lupron causes to not only people who have taken it for its intended purpose - prostate cancer, but people who have taken it for precocious puberty. Lupron is one of the class of drugs used as a puberty blocker.
It causes so much harm to people that it has had more than 10,000 adverse events - including crumbling skeleton, loose teeth, fits, abnormal pain, in some cases sudden death. Patients harmed by this drug are preparing a class action against the manufacturer.
Can you point to these generations of follow-up studies with the large population of individuals prescribed such drugs for precocious puberty and show where they prove that they are free from long term harm?